To understand how people value information from diagnostic technologies, we reviewed and analyzed published willingnessto-pay (WTP) studies on the topic. Methods: We searched PubMed for English-language articles related to WTP for diagnostic laboratory tests published from 1985 through 2011. We characterized methodological differences across studies, examined individual-and technology-level factors associated with WTP, and summarized median WTP values across different diagnostic tests. Results: We identified 66 relevant WTP studies. Half focused on oncology, while others analyzed infectious diseases (n ¼ 11, 16.1%) and obstetric or gynecological conditions (n ¼ 8, 11.7%), among others. Most laboratory tests included in studies were biological samples/genetic testing (n ¼ 44, 61.1%) or imaging tests (n ¼ 23, 31.9%). Approximately one third of the analyses (n ¼ 20, 30.3%) used discrete-choice questions to elicit WTP values. Higher income, education, disease severity, perceived disease risk, family history, and more accurate tests were in general associated with higher WTP values for diagnostic information. Of the 44 studies with median WTP values available, most reported a median WTP value below $100. The median WTP value for colon or colorectal cancer screening ranged from below $100 to over $1000. Conclusions: The contingent valuation literature in diagnostics has grown rapidly, and suggests that many respondents place considerable value on diagnostic information. There exists, however, great variation in studies with respect to the type of technologies and diseases assessed, respondent characteristics, and study methodology. The perceived value of diagnostic technologies is also influenced by the study design and elicitation methods.
Introduction
Predictive testing, one of the fastest growing areas of health care, has been shown to be one of several important drivers of health cost increases in the United States [1, 2] . In moving toward costconscious care, the value of screening and diagnostic tests has been central to policy discussions [3] . Many studies have examined the value of test information by using a conventional costeffectiveness framework [4] . Under this framework, information from diagnostics is typically valued exclusively for its ability to improve medical decision making and subsequent outcomes. In practice, however, patients may value information from a diagnostic test whether or not the information effects treatment change [5, 6] . For example, test information may reduce uncertainty and provide reassurance, assist in life-planning decisions, and benefit future treatment decisions among the patient's family.
Contingent valuation, a standard economic measure of willingness to pay (WTP) for health interventions, offers researchers flexibility to investigate how people value a wide range of health benefits. WTP for a specified health improvement is defined as the maximum amount of money an individual could pay for the health improvement and still consider himself or herself better off [7] . WTP valuation can be used in cost-benefit analysis by estimating the cost of the intervention against the WTP values of the indicated improvement [8, 9] . Those instances in which the WTP value is greater than the cost of the invention provide evidence of consumer surplus [10] . Observers in the field have identified challenges in measuring and using WTP values, including framing effects and ethical objections to asking people directly to value health improvements. Still, the WTP literature in health care has grown over the past few decades, with applications to different disease areas, treatment modalities, and survey methods [9, [11] [12] [13] [14] [15] .
In particular, the applications of WTP estimation have emerged for diagnostic testing. Our review examines the perceived value of test information beyond the conventional cost-effectiveness framework, focusing on the direction and magnitude of preferences reported in WTP analyses. We also investigate the methods used to capture preferences and examine methodological differences across studies to better understand discrepancies in WTP values. Our goal was to understand how people may value diagnostic tests and how the WTP value varies with individual factors (e.g., age, income, and disease history) and test characteristics (e.g., accuracy). Finally, we discuss how this information can be used to help capture more completely the value of diagnostic technologies, and the implications for clinical and policy decisions.
Methods
We searched for studies using the PubMed database in January 2012 by inputting the following terms: (willingness to pay OR contingent valuation) AND diagnostic (n ¼ 500) ( Fig. 1 ). All English-language articles published from 1985 through 2011 were eligible for screening (n ¼ 486). We screened all articles' titles and abstracts for potential inclusion. We then obtained and reviewed the citation list of those articles considered for potential inclusion to ensure completeness of the PubMed search. Of these 486 abstracts, we excluded 368 studies that were cost-effectiveness analyses/cost-utility analyses/costbenefit analyses (n ¼ 191), did not assess a diagnostic technology (n ¼ 96), did not report any WTP value (n ¼ 42), were reviews, editorials, or methods (n ¼ 30), or were not eligible for other reasons (e.g., comprised only study protocols) (n ¼ 9). Finally, we obtained the full text of the identified publications (n ¼ 118) and manually screened the text to select studies that reported an original WTP estimate for a diagnostic technology. After review of the full text, an additional 52 articles were excluded, leaving a final sample of 66 studies.
Each WTP article was abstracted by using a standard data auditing form, which contained three major sections: 1) methodology (e.g., publication information, intervention, type of diagnostic, disease classification, sample, mode of administration, and elicitation methods); 2) median/mean WTP values; and
3) factors associated with the WTP estimate. We first characterized methodological differences across studies. Then, we examined individual-and diagnostic-level factors associated with WTP. Finally, we summarized WTP values across different diagnostic technologies on the basis of studies that reported median values.
We also examined whether the WTP studies used one of four commonly used elicitation methods: 1) discrete-choice questions, 2) bidding game, 3) payment card, and 4) open-ended questions. Discrete-choice questions (also referred to as close-ended, dichotomous-choice, or binary questions) present respondents with a WTP value, which they either accept or reject, often followed by additional follow-up discrete-choice questions to identify a distribution of WTP values. A bidding game presents respondents with an initial amount, which they may either accept or reject and then bid up, or down, in defined increments until their maximum WTP values are reached. By asking a series of questions with yes/no bids, the bidding game method may be considered an iterative version of the discrete-choice method. In contrast to the iterative nature of the bidding game method, the payment card method presents simultaneously a range of bids and asks respondents to circle the amount representing the most they would be willing to pay. Finally, in an open-ended questionnaire, respondents are asked directly for their maximum WTP value, without presenting respondents any possible values.
Results
The number of published WTP studies pertaining to diagnostic tests has grown rapidly over time, increasing from 3 published from 1985 to 1993 to 23 from 2006 to2011 ( Table 1 ). Half of diagnostic WTP studies have focused on oncology, 16.1% pertained to infectious diseases, and 11.7% focused on obstetric or gynecological conditions. Most laboratory tests were biological samples (e.g., blood, tissue, and urine)/genetic testing (n ¼ 44, 62.0%) or imaging (n ¼ 23, 31.0%). Biological samples and/or genetic tests were especially well represented among WTP studies pertaining to oncology, infectious disease, obstetricsgynecology, and neurology (Table 2 ). Furthermore, imaging tests were frequently used in oncology and obstetrics/gynecology studies, but not for infectious disease or endocrinology. Table 1 summarizes methodological differences across the 66 WTP studies. The most common mode of administration was self-administered questionnaires (36.4%), followed by Web-based instruments (15.2%), in-person interviews (13.7%), telephone surveys (13.6%), and mail surveys (7.6%).
Methodological Differences in WTP Valuation

Mode of administration
Elicitation methods
Approximately one third (30.3%) of the studies used discretechoice questions, followed by payment cards (15.2%), bidding games (13.6%), and open-ended questions (10.6%) ( Table 1) . Other studies used more than one contingent valuation method in the elicitation process [6, [16] [17] [18] [19] [20] or compared WTP values derived from different approaches [21] [22] [23] [24] [25] [26] .
Survey respondent and sample size
Most studies used a sample of patients or at-risk populations (49.3%), or respondents from the general population (34.5%) ( Table 1 ). Parents served as proxy respondents for children for WTP elicitations if children were the subjects of the diagnostic test [8, [27] [28] [29] . Other studies compared WTP responses from different sample populations, such as patients, physicians, managed care organization executives, or the general public [30] [31] [32] [33] [34] . The sample sizes varied substantially across articles, ranging from 3 radiologists in one study that evaluated the added value of biliary contrast [30] to 6352 parents in a study that evaluated WTP for celiac disease screening [27] . Roughly half of the studies had samples of 101 to 500 respondents.
Factors Influencing WTP Values for Diagnostic Technologies
Demographic and socioeconomic characteristics
The association between WTP values and demographic characteristics varied across studies. Some studies indicated that WTP values were positively influenced by older age [21, [35] [36] [37] [38] [39] [40] [41] , sex [21, 25, 39] , and majority race/ethnicity [39, 42, 43] , with females and white Americans generally having higher WTP values, whereas others found no relationship between WTP and those characteristics [20, 35, [44] [45] [46] . Most studies indicated that WTP values increased with respondent income [19] [20] [21] 26, 35, 36, 38, 43, [47] [48] [49] [50] and education [37] [38] [39] 47, 51] .
Disease severity, risk perception, and family history
Disease severity appeared to be positively associated with WTP values [46, 48, 52] . In a cohort of 406 adults with type 2 diabetes, for [34] included patients and individuals from the general population.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 9 7 -8 0 5 example, patients with severe diabetic retinopathy had significantly higher WTP values for screening for diabetic retinopathy than did patients with mild diabetic retinopathy [46] . In contrast, a study by Severens et al. [44] found that WTP values were independent of the perceived severity of the disease in testing the seroprevalence of antibodies to Histoplasma capsulatum.
Individuals with higher perceived disease risk or who were more health conscious tended to have higher WTP values for diagnostic technologies [6, 21, 37, 43, 49, [53] [54] [55] . Neumann et al. [6] found that WTP values were consistently higher when respondents were presented with an ex ante risk of developing the disease of 25% compared with 10% and that the results were consistent across scenarios presenting tests for Alzheimer's disease, arthritis, breast cancer, and prostate cancer. Another study in Scotland found that women were willing to pay more for cervical cancer screening if they were presented with an increased chance of dying from the disease [41] . In a study of 397 Japanese women aged 50 to 59 years, WTP values were higher among those who were more concerned about their health and had received mammography for breast cancer screening than among women who had never received mammography [55] .
Having family history of the disease, which may affect the individual's perceived risk, also was positively associated with WTP [43, 49, 53, 55] . Wagner et al. [43] , for example, found that women whose sister, mother, or daughter had had cancer were willing to pay significantly more and to travel further to obtain a free mammogram.
While risk perception was associated with increased WTP values, it was less clear whether WTP values were influenced by prior test results or prior disease status. For example, Liang et al. [56] reported that women who had prior benign breast diseases were less willing to pay for a test with 95% accuracy than were women without the history. In contrast, Stephens et al. [45] found that while most women (135 of 150 eligible subjects) wanted a prenatal sonogram during pregnancy, their WTP values and the number of sonograms they desired did not vary by prior pregnancy. In addition, WTP values for cervical cancer screening did not vary by prior smear status in women aged 20 to 59 years in Scotland [20] .
Test accuracy
Diagnostic test accuracy generally influenced both the choice of the test and the WTP values of the test. One study showed that although parents generally had a high tolerance for false-positive newborn screening results, the median WTP values to avoid a false-positive screening result were significantly lower for parents whose child had experienced a false-positive screening result ($0) than for parents of children with normal screening results ($100) (P o 0.001) [28] . Liang et al. [56] found that women were willing to pay an average of $611 to have a new noninvasive breast cancer diagnostic test instead of a biopsy if the test was as accurate as biopsy; however, WTP values decreased to $308 if the test had only 95% accuracy. In a survey of 175 female patients, Raab et al. [37] estimated an increased median WTP from $50 to $100 as the performance of a new Papanicolaou test increased, regardless of their perceived risk of cervical cancer. Schiffner et al. [57] reported that the WTP value for a standard practice in detecting malignant melanoma was at least 40% below that of a hypothetical test with perfect accuracy [57] . Table 3 provides specific examples selected from the 44 studies that reported median WTP values. Most reported median WTP values below $100. Within this range of WTP values, there was wide variation in test complexity, from simple contrast agent imaging [30] to positron emission tomography screening [36, 49] . Similarly, these WTP values contained a variety of diseases for which to test. Most diagnostics for infectious diseases and sexually transmitted diseases were estimated to have WTP values of less than $100. Among technologies with median WTP values in the range of $101 to $500, the majority of the diagnostic tests were for cancer. Interventions represented within this WTP value range generally used more complicated modalities (e.g. magnetic resonance imaging [19] , dual-energy x-ray absorptiometry [39] , and mammography [6] ) than did those with a WTP value below $100. Several diseases associated with aging were represented in this WTP value range, such as some cancers, osteoporosis, arthritis, and Alzheimer's disease.
Median WTP Values of Diagnostic Tests
Finally, eight studies reported median WTP values greater than $1000. These studies examined diagnostic technologies relevant to cancer [25, 26, 52, 54] and to expectant parents (e.g., karyotype analysis for Down's syndrome [58] , prenatal ultrasound [59] , amniocentesis for chromosomal disorders [35] , and genetic prenatal test for developmental disability [29] ).
To further understand discrepancies in WTP values, we examined studies that evaluated similar diagnostic technologies, using colon or colorectal cancer screening as an example. Table 4 summarizes characteristics of nine articles related to colon and colorectal cancer screening, including biological (e.g., fecal occult blood, colonoscopy) and imaging (e.g., computed tomography colonography, endoscopy) tests. Depending on the elicitation methods, six studies reported median WTP values below $100 [21, 24, 25, 50, 60, 61] , two reported median WTP values between $100 and $500 [22, 62] , and two reported median WTP values over $1000 [25, 26] . One study by Frew et al. [25] identified a large difference between open-ended and close-ended WTP questions for colorectal cancer screening. Depending on the starting bid (larger starting bids having larger mean WTP estimates), the median WTP estimate could be 20 times as large for close-ended (£946-£1009) compared with open-ended questions (£30-£50) [25] .
Discussion
We reviewed published WTP studies pertaining to diagnostic technologies over the past three decades. The number of studies has grown steadily, with more than half focused on cancer. Most of these WTP studies examined diagnostics by using biological samples or genetic testing. However, a great variation exists in the type of technologies assessed, disease of interest, respondent characteristics, and study methodology-all of which may influence the perceived value of a diagnostic test.
Despite numerous cost-utility analyses demonstrating good value for money of many laboratory diagnostic tests, relatively little has been published characterizing preferences for test information in detail-specifically, how preferences vary by patient factors, the condition being evaluated, or the diagnostic modality. Our review suggests that at the individual level, [31, 32, 70] Malaria testing [34, 48] HIV testing [78] Combination TB, HIV, and syphilis [16] Musculoskeletal Osteoporosis screening [71] Oncology Cervical cancer screening [68] Colon cancer screening [21, 24, 25, 50, 60, 61] Prostate -specific antigenscreening [18, 55, 76, 79] Breast cancer genetic screening [33, 55] Malignant melanoma screening [57] PET screening for unspecific cancer [36, 49] Florescent oral cancer screening [67] Obstetrics/ gynecology Antenatal screening for cystic fibrosis [63] [64] [65] Other Contrast agent in imaging of biliary tree [30] Celiac disease screening [27] 101-500
Endocrinology
Newborn screening for metabolic disorders [28] Musculoskeletal DXA scan for osteoporosis screening [39] Arthritis screening [6] Oncology Prostate cancer screening [6] Breast cancer screening [6] Colon cancer screening [22, 62] Neurology Hypothetical blood test to identify Alzheimer's disease [6, 38, 66] Other MRI/CT angiography [19] 501-1000 NA
41000
Oncology Colon cancer screening [25, 26] PET for suspected lung cancer [52, 54] Colon cancer screening [25, 26] 
Obstetrics/ gynecology
Prenatal ultrasound [59] Amniocentesis for chromosomal disorders [35] Genetic prenatal testing for idiopathic developmental disability [29] Karyotype analysis for Down's syndrome [58] CT, [X-ray] computed tomography; DXA, dual-energy X-ray absorbtiometry; HIV, human immunodeficiency virus; MRI, magnetic resonance imaging; NA, not applicable/available; PET, positron emission tomography; TB, tuberculosis; WTP, willingness to pay.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 9 7 -8 0 5 differences in risk perception, risk tolerance, and personal or family/acquaintance history may make some individuals more willing to pay larger amounts of money to identify whether they have a disease or risk factor. At the disease level, more severe conditions and diseases without a controllable risk factor, such as some cancers and congenital abnormalities, are associated with higher WTP estimates; colon cancer diagnosis [21, 22, [24] [25] [26] 50, [60] [61] [62] and perinatal screening [28, 29, 35, [63] [64] [65] are examples. Further, at the technology level, more accurate tests tend to have higher WTP estimates [6, 56, 60, 66] , suggesting that they are perceived as having more use for medical decision making and perhaps for greater reductions in diagnostic uncertainty. Our review also showed that comparatively simple imaging methods (e.g., contrast agents [30] and fluorescence methods [67] ) generally have lower WTP estimates than do more technologically complicated imaging modalities (e.g., positron emission tomography [52, 54] and magnetic resonance imaging [19] ). This may not be due to patients' inherent preference for complicated technologies, but rather the perception that the tests have better diagnostic accuracy.
The perceived value of diagnostic technologies also seems to be influenced by the study design and elicitation methods, even for similar laboratory tests. Our review of studies related to colon and colorectal cancer screening found substantial differences in median WTP values, ranging from $100 or less [21, 24, 25, 50, 60, 61] to more than $1000 [25, 26] . Although several potential explanations for the WTP difference have been suggested (e.g., framing and anchoring), research to date has not yet identified which, if any, are most impactful. It is also not clear which of the elicitation methods provides a more accurate estimate of maximum WTP value or a reproducible method, or yields consistently higher/lower values than others. For instance, among articles comparing different contingent valuation methods, one study reported higher WTP values (for Chlamydia screening [23] ) from discrete-choice questions than from payment cards, while two studies reported higher WTP values (for colorectal cancer screening [21, 24, 50] ) for payment cards than for open-ended questions. Another study, however, reported identical median WTP values for colorectal screening for payment cards and open-ended questions, though increased WTP values for discrete-choice questions [25] . That same researcher, in a later analysis [26] , reported higher WTP values for a bidding game than for either payment scale or open-ended questions. Our findings highlight the need for evaluating how different WTP elicitation techniques (e.g., bidding game and open ended questions) and design features (e.g., staring bid and various qualifiers used to prime the open-ended question) may influence results and cross-study comparability.
Because WTP studies offer a conceptually appealing approach to attaching a value to a diagnostic medical technology, they could help inform the setting of prices or insurance co-pays, and be incorporated in economic evaluations of new diagnostics, such as cost-benefit analysis [8, 9] . Previous research has suggested that they may help demonstrate the value for diagnostics not only to improve medical decision making but also to benefit patients irrespective of treatment by reducing uncertainty [5, 6] . For WTP to be informative, however, there must be a level of validity and reliability to the WTP measurement. A need for further research is underscored by the differences in WTP estimates produced when different methods were used to estimate WTP for the same test (e.g., colon cancer screening).
There are some limitations to our review. First, focusing on WTP values for treatments and interventions, rather than diagnostics, may lead to different conclusions about the comparability of various WTP methods. Comparing WTP values for diagnostics and treatments or interventions is outside the scope of this study. Second, our summary of WTP values was limited to a subset of articles that reported median values. Nonreporting of median results in approximately one third of the articles, and variation in study methodologies made comparisons across studies difficult. Third, WTP values depend on income and therefore may vary by country. In our analysis of colon and colorectal cancer screening, among studies reporting median WTP values of $100 or less, one was conducted in the United States [61] , four in the United Kingdom [21, 24, 25, 50] , and one in Australia [60] . Both studies that reported median WTP values between $100 and $500 used a US sample [22, 62] , and both studies that reported median WTP values over $1000 used a UK sample [25, 26] . More research on whether geographical or jurisdictional factors influence WTP would be helpful.
Our review adds to current understanding about the value of diagnostic technologies beyond the conventional cost-effectiveness framework. Our findings also shed light on discrepancies in preferences for and value of test information with respect to individual characteristics, the disease in question, as well as the performance characteristics of the test. Despite its limitations, WTP analysis provides a standard, well-accepted approach to capturing preferences, which can be used to inform whether a technology represents good value for money. Further research is needed to identify the relative accuracy, precision, and pros and cons of various WTP measurement techniques, as suggested by great variation in WTP estimates across studies examining colon and colorectal cancer screening [21, 22, [24] [25] [26] 50, [60] [61] [62] . In addition, further research is needed to identify how methodological choice and population sampled can result in differences in WTP estimates. Such research would be helpful to generate guidelines and "best practices" that can help guide the WTP field to inform decision makers. This research could assist decision makers in using the information created by WTP studies to align the prices and copayments for diagnostic medical technologies more closely to the total value generated by their use.
